enGene Holdings Inc. (ENGN) jumped 53.08% to $9.20, up $3.19, after its press release showing that its gene-therapy candidate detalimogene achieved a 62% complete response rate at six months in the Phase 2 LEGEND trial for high-risk, BCG-unresponsive non-muscle-invasive bladder cancer.
On the day of the announcement, ENGN experienced unusually heavy trading volume as investors reacted to the data. The stock's 52-week range is $2.65 - $9.20.
https://www.nasdaq.com/articles/engene-shares-surge-53-strong-bladder-cancer-gene-therapy-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.